Trial · NCT02252172
Adverse events1,208
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,208
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Lenalidomide + Dexamethasone (Rd) | 148 | 365 | |
| other | Anaemia | Blood and lymphatic system disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 154 | 364 | |
| other | Leukopenia | Blood and lymphatic system disorders | Lenalidomide + Dexamethasone (Rd) | 42 | 365 | |
| other | Leukopenia | Blood and lymphatic system disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 73 | 364 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Lenalidomide + Dexamethasone (Rd) | 48 | 365 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 72 | 364 | |
| other | Neutropenia | Blood and lymphatic system disorders | Lenalidomide + Dexamethasone (Rd) | 167 | 365 | |
| other | Neutropenia | Blood and lymphatic system disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 224 | 364 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Lenalidomide + Dexamethasone (Rd) | 76 | 365 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 82 | 364 | |
| other | Atrial Fibrillation | Cardiac disorders | Lenalidomide + Dexamethasone (Rd) | 33 | 365 | |
| other | Atrial Fibrillation | Cardiac disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 30 | 364 | |
| other | Vertigo | Ear and labyrinth disorders | Lenalidomide + Dexamethasone (Rd) | 19 | 365 | |
| other | Vertigo | Ear and labyrinth disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 22 | 364 | |
| other | Cataract | Eye disorders | Lenalidomide + Dexamethasone (Rd) | 78 | 365 | |
| other | Cataract | Eye disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 88 | 364 | |
| other | Vision Blurred | Eye disorders | Lenalidomide + Dexamethasone (Rd) | 19 | 365 | |
| other | Vision Blurred | Eye disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 30 | 364 | |
| other | Abdominal Pain | Gastrointestinal disorders | Lenalidomide + Dexamethasone (Rd) | 43 | 365 | |
| other | Abdominal Pain | Gastrointestinal disorders | Daratumumab + Lenalidomide + Dexamethasone (DRd) | 59 | 364 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02252172/events